Fig. 5
From: Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway
Metformin activated AMPK/autophagy signaling pathway in prostate cancer cells. a DU145 and PC3 cells were treated with metformin for 24 h and the expressions of p62/SQSTM1, AMPK, p-AMPK, LC3‐I and LC3‐II levels were analyzed by Western blot. b, c CCK8 assay and Western blot analysis were conducted after the cells had been treated with AMPK siRNA for 24 h first and then metformin for another 24 h. Numbers under the bands (LC3‐II for LC3) are the relative expression values to that of LC3I. Data are presented as the mean ± SD. ***p < 0.001 compared with the control group. Met, Metformin